• Profile
Close

Zydus Cadilla gets USFDAs final nod for Pindolol tablets

UNI Aug 23, 2017

Pharma Major, Zydus Cadila has received the final approval from the USFDA to market Pindolol Tablets USP, 5 mg and 10 mg.

 

 

 

Pindolol belongs to a class of medication called beta-blockers and is used to treat hypertension. The drug will be manufactured at the group's formulations manufacturing facility at the Pharma SEZ, Ahmedabad. The sale of Pindolol tablets is estimated at USD 83.59 million. Source: 1MS Health, IMS National Sales Perspective Audit. MAT June 2017, extracted August 2017. The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
 

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay